• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Canadian Journal of Kidney Health and Disease

    Canadian Journal of Kidney Health and Disease

    JournalISSN 2054-3581eISSN 2054-3581中科院 医学 4区

    年发文量

    研究主题

    论文(968)

    排序
    1Implementation of a Peer Support Initiative for Kidney Transplant Recipients and Living Kidney Donors: A Program Report on the Transplant Ambassador Program
    Susan Q. McKenzie,Kyla L. Naylor,Seychelle Yohanna, Jamal El Ali, Courtney Gibson, Fiona Gilfillan, Barb Longo, Christine Pisapia,Marian Reich, Mike Santavy,Amit X. Garg

    Purpose of program The Transplant Ambassador Program (TAP) is a patient-led, volunteer-driven support program that connects patients with kidney failure and potential living kidney donors to kidney transplant recipients and living kidney donors. TAP was developed to address a peer support gap identified by patients, by providing emotional support, practical guidance, and one-on-one conversations. Sources of information Lived experience of patients with kidney failure (e.g., kidney transplant recipients) and living kidney donors, information from existing peer support programs, input from individuals working in advanced chronic kidney disease (CKD) and dialysis clinics (e.g., nephrologists and nurses), and input from provincial transplant and kidney care organizations. Methods TAP was developed primarily by patients (i.e., kidney transplant recipients and living kidney donors), in partnership with researchers and kidney health care professionals. Transplant ambassador volunteers lead and run the program, including developing and delivering training to transplant ambassadors. Implementation of TAP began in November 2017 at half of the 27 CKD programs in Ontario, Canada, as part of a multicomponent cluster-randomized clinical trial. Key findings TAP has been operating for over eight years, expanding to all of Ontario’s CKD programs and to Atlantic Canada, with over 200 active transplant ambassadors. Since its launch, TAP has logged over 10,000 conversations with patients and potential donors and facilitated 25 educational webinars on kidney transplantation. Limitations Most patient referrals to TAP are initiated by healthcare professionals, who connect patients to the program. In some hospitals, low referral rates have resulted in transplant ambassadors stepping away due to a lack of work. Implications TAP demonstrates that patients can scale a volunteer-run, peer support model provincially and nationally. Patient volunteers have led this program and embedded it into kidney care, with support from provincial organizations, reaching many patients with CKD and potential living kidney donors.

    2026
    引用
    AI阅读
    加入学术空间
    2A Hitchhiker’s Guide to Precision Medicine in Glomerulonephritis
    Sharanya Ramesh MD, PhD, Warren Wong MA, Ian Goodall-George BA, Kevin Yau MD, MSc, Mallory L Downie MD, PhD

    Purpose Glomerulonephritis (GN) comprises a heterogeneous group of immune-mediated kidney diseases and is the third leading cause of kidney failure. Although increasing clinical trials in this area have led to new therapeutic options, selecting the right treatment for the right patient remains challenging. We review current precision medicine initiatives that integrate deep clinical phenotyping with genomics and multi-omics approaches to identify pathway-specific therapies and refine risk stratification. We also discuss how these strategies may reshape clinical trial design and treatment selection in GN. Sources of Information Literature was identified through PubMed and Google Scholar from inception to 2026. Patient perspectives were informed by engagement with patient partners. Methods Search terms included “precision medicine”, “nephrology”, and “glomerulonephritis”. Key Findings Advances in genetics, multi-omics profiling, and large collaborative cohorts have revealed molecularly distinct subtypes within GN, enabling biomarker-guided diagnosis, improved risk stratification, and targeted therapy. Initiatives such as the Kidney Precision Medicine Project and the Nephrotic Syndrome Study Network (NEPTUNE) integrate kidney tissue, blood, urine, and clinical data to identify actionable biological pathways. The NEPTUNE Match initiative aims to align patients with clinical trials most likely to benefit them based on their molecular profiles. Disease-specific examples, including PLA2R antibody monitoring in membranous nephropathy and proof-of-concept studies in focal segmental glomerulosclerosis, highlight the potential of precision medicine approaches that can translate into clinical care. Genetic variation at the human leukocyte antigen (HLA) locus may represent a shared risk factor across GN subtypes. Incorporating sex- and gender-based analyses into precision frameworks will be essential to ensure appropriate risk stratification and therapeutic selection. Importantly, patient-centered initiatives demonstrate high levels of engagement and willingness to participate in precision medicine research. Collectively, these findings support a paradigm shift toward personalized GN management. Limitations A systematic review was not conducted, and our search was restricted to English-language articles.

    2026
    引用
    AI阅读
    加入学术空间
    3Racial Disparities in Kidney Failure among Black People in Ontario: A Population-Based Study
    Laura Seliske, Jane Ip, Devron J. Swaby, Arrti A. Bhasin, Sabrina Padewski, Aisha Tehseen, Caitlin McGarry, Mandeep Bumbra, Tabo Sikaneta,Istvan Mucsi,Ayodele Odutayo, Paulette Lewis,

    Background Ontario recently designated Black people aged 40 and older as a high-risk group for annual chronic kidney disease (CKD) screening in primary care, yet population-level data have been limited. Objective To describe and compare kidney failure incidence, prevalence, pre-dialysis care, treatment modality, and mortality between Black and White individuals in Ontario. Design Population-based descriptive analysis of provincial administrative health data, 2017–2024. Setting All adult kidney programs in Ontario, Canada, captured in the Ontario Renal Reporting System. Patients and Measurements All individuals receiving maintenance dialysis were included. Age-standardized rates of dialysis initiation, prevalence, and mortality were compared between Black and White individuals. Time from first meeting advanced CKD care lab criteria (eGFR <15 mL/min/1.73 m 2 or 2-year kidney failure risk ≥10%) to dialysis initiation and home dialysis uptake were compared. Results Among 26,042 incident dialysis patients, 1,674 (6.4%) were Black and 15,888 (61.0%) White. Black individuals were younger at initiation (median 62.0 vs. 69.9 years) with lower eGFR (6.7 vs. 8.3 mL/min/1.73 m 2 ). In 2024, age-standardized incidence of dialysis initiation among Black individuals was 1.8-fold higher (292.1 vs. 162.4 per million) and prevalence was 3.5-fold higher. Among those meeting advanced CKD care lab criteria, Black individuals had a shorter median interval to dialysis (593 vs. 666 days) and lower home dialysis uptake (18.8% vs. 24.1%). Age-standardized mortality was lower. Limitations Self-reported racialized identity was ascertained from administrative data and has not been formally validated, with a rising proportion recorded as “unknown” (19.6% by 2024); mortality and modality comparisons were standardized for age but not comorbidity; kidney transplantation was not assessed; and all analyses were restricted to individuals who reached maintenance dialysis. Conclusions Black individuals in Ontario experience higher kidney failure rates, begin dialysis younger with more advanced disease, and progress more rapidly from advanced CKD care to dialysis. These findings support Ontario’s recent recommendation of annual CKD screening for Black individuals aged 40 and older in primary care and underscore the need for earlier detection and intervention.

    2026
    引用
    AI阅读
    加入学术空间
    4Systematic Review of the Cost-Utility of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Chronic Kidney Disease Management
    Ronald Watema-Lord BSc, PharmD, Feng Xie BSc, MSc, PhD,Chiranjeev Sanyal BPharm, MSc, PhD

    Purpose of review Chronic kidney disease (CKD) represents a progressive and severe medical condition that imposes a substantial economic burden. This systematic review aimed to summarize the available evidence regarding the costs and cost-utility of SGLT2 inhibitors in managing CKD. Sources of information A systematic literature search was conducted from inception to November 07, 2025, using MEDLINE, EMBASE, and Scopus databases. Methods Titles and abstracts were screened, followed by an eligibility assessment of full texts. The quality of the studies was evaluated using the Quality of Health Economic Studies (QHES) and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklists. Cost-utility results were synthesized narratively. Key findings Thirteen cost-utility studies met the inclusion criteria, evaluating Dapagliflozin, Empagliflozin, and Canagliflozin. The addition of Empagliflozin or Dapagliflozin to standard care (SoC) was cost-effective compared with SoC alone in patients with chronic kidney disease (CKD), regardless of type 2 diabetes (T2D) status. Among CKD patients with T2D, SGLT2 inhibitors combined with SoC were cost-saving in high-income countries from a health system perspective; however, Dapagliflozin was not cost-effective when compared to Canagliflozin. No study fulfilled all criteria of the QHES and CHEERS checklists. Limitations This systematic review has several limitations, including restriction to English-language studies, potential subjectivity in methodological and reporting quality assessments, and possible publication bias. In addition, heterogeneity in study settings, interventions, and service utilization limits direct comparisons across studies, although the findings provide valuable insights into the cost-utility of SGLT2 inhibitors for CKD management.

    2026
    引用
    AI阅读
    加入学术空间
    5Opposing Effects of Fibroblast-Specific Adenosine A2b Receptor Knockout on Kidney Fibrotic and Inflammatory Gene Programs in Mice with Obstructive Uropathy
    Madiha Zahra Syeda,Harmandeep Kaur,Duc Tin Tran, Sri Nagarjun Batchu, Emily S. H. Yeung, Lisa Y. Q. Hong, Youan Liu,Suzanne L. Advani, Holger K. Eltzschig, Darren A. Yuen,Andrew Advani

    Background The purine nucleoside adenosine has established anti-inflammatory effects whilst also being reported to promote organ fibrosis by signaling through the adenosine A2a and A2b receptors. Objective Here, we examined the consequences of deletion of the adenosine A2b receptor from fibroblasts in mice with obstructive uropathy caused by unilateral ureteral obstruction (UUO). Methods Experiments were performed in C57BL/6N mice after UUO, and in mouse embryonic fibroblasts (MEFs) stimulated with recombinant transforming growth factor-β1 (TGF-β1). Tamoxifen-inducible fibroblast-specific adenosine A2b receptor knockout mice (A2B FibKO ) were generated by breeding Adora2b fl/fl mice with Col1a2 CreER + mice, and these mice were compared with Adora2b fl/fl mice (A2B Ctrl ) 14 days after sham or UUO surgery. Results mRNA levels of Adora2b , the gene that encodes the adenosine A2b receptor, were increased in mice with UUO, and knockdown of Adora2b diminished fibrotic gene upregulation in MEFs. In A2B FibKO mice with UUO, fibroblast-specific adenosine A2b receptor knockout diminished upregulation of mRNA levels of fibrotic genes but increased mRNA indices of kidney inflammation and tubule injury. These gene expression changes were reflected in a numerical but non-significant reduction in interstitial fibrosis, with persistent tubule epithelial programmed cell death and macrophage accumulation. Expression of Adora2a remained expectedly elevated in UUO kidneys. Conclusions The findings illustrate the bidirectional effects of the adenosine A2b receptor in kidney fibrosis and inflammation, and the relatively small consequences of its cell-specific gene deletion, at least in UUO mice. Specific targeting of adenosine receptors to improve outcomes for kidney disease represents a therapeutic challenge.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 968 篇论文

    高被引作者

    作者引用发文
    Louise Moist89836
    Swapnil Hiremath86029
    Sean Bagshaw8479
    Amit Garg82892
    Kappel Joanne76927
    Brenda Hemmelgarn73343
    Navdeep Tangri69047
    Jennifer M. Macrae65027
    Charmaine E Lok63317
    Edward G. Clark61220

    高产作者

    作者引用发文
    Amit Garg82892
    Adeera Levin56868
    Manish M Sood54052
    Karthik K Tennankore46448
    Navdeep Tangri69047
    Brenda Hemmelgarn73343
    Knoll Greg50840
    Marcello Tonelli45938
    Louise Moist89836
    Braden Manns56336

    相关期刊

    Clinical nephrology
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
    Seminars In Dialysis
    Néphrologie & Thérapeutique
    International journal of nephrology and renovascular disease
    Kidney medicine
    Nephrology
    Seminars in Nephrology
    Advances in Chronic Kidney Disease
    Renal Replacement Therapy